The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Development and implementation of a digital health intervention (DHI) electronic patient-reported outcome measure (ePROM) platform to monitor patients with cancer.
 
Matheus Soares Rocha
No Relationships to Disclose
 
Alessandra Menezes Morelle
Stock and Other Ownership Interests - Thummi
Honoraria - GlaxoSmithKline; MSD Oncology; Novartis; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Lilly; MSD Oncology; Novartis; Roche
Speakers' Bureau - Lilly; MSD Oncology; Novartis; Roche
Patents, Royalties, Other Intellectual Property - I am CEO and co-founder of Thummi, a digital platform for oncology patients.
 
Paulo Alfredo Casanova Schulze
No Relationships to Disclose
 
Pedhro Lennon Cezário Freitas
No Relationships to Disclose
 
Simone Bassani Fardo
No Relationships to Disclose
 
Lucas Trindade Sales
No Relationships to Disclose
 
Carlos Eurico Pereira
No Relationships to Disclose
 
Vinicius Agibert Souza
No Relationships to Disclose
 
Carlos H. Barrios
Stock and Other Ownership Interests - MedSIR; Tummi
Honoraria - Adium Pharma; AstraZeneca; Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Lilly; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi; Zodiac Pharma
Consulting or Advisory Role - AstraZeneca; Libbs; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech; United Medical
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Aveo (Inst); Bayer (Inst); Biomarin (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Covance (Inst); Daiichi Sankyo (Inst); Exelixis (Inst); Exelixis (Inst); Gilead Sciences (Inst); ICON Clinical Research (Inst); INC Research (Inst); IQvia (Inst); Janssen (Inst); LabCorp (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Nuvisan (Inst); OBI Pharma (Inst); Parexel (Inst); Parexel (Inst); Pfizer (Inst); PharmaMar (Inst); PPD Global (Inst); PSI (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Servier (Inst); Syneos Health (Inst); Takeda (Inst); TRIO US (Inst); Worldwide Clinical Trials (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS Brazil; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech